Myasthenia gravis is a chronic autoimmune condition that disrupts the way nerves and muscles communicate, causing muscle weakness that worsens with activity and improves with rest. Treatment focuses on managing symptoms, slowing disease progression, and helping people maintain their quality of life through a combination of medications, surgery, and lifestyle adjustments.

How Treatment Helps People with Myasthenia Gravis

When someone receives a diagnosis of myasthenia gravis, one of the first questions that comes to mind is whether the condition can be managed effectively. While there is currently no cure for myasthenia gravis, the outlook for most people is positive because current treatments can often control symptoms quite well. The main goals of treatment are to reduce muscle weakness, prevent serious complications like breathing difficulties, and allow people to return to their daily activities with as few limitations as possible.^[1][2]

Treatment decisions depend on several factors, including which muscles are affected, how severe the weakness is, the patient’s age, and whether other health conditions are present. For some people, symptoms remain limited to the eyes, a form called ocular myasthenia gravis. For others, the weakness spreads to facial muscles, throat, limbs, and sometimes even the muscles needed for breathing, which is called generalized myasthenia gravis. The type and severity of the condition guide doctors in choosing the most appropriate treatment approach.^[3][4]

Medical societies and experts have developed clinical guidelines to help doctors make informed decisions about treatment. These guidelines are based on years of research and clinical experience and are regularly updated as new therapies become available. The treatment journey often involves working closely with a neurologist or neuromuscular specialist who has experience with myasthenia gravis. Because the condition can behave differently from one person to another, treatment plans must be individualized.^[11][12]

It’s important to understand that myasthenia gravis is a chronic condition with symptoms that can come and go. Many people experience flare-ups, when symptoms become more troublesome, followed by periods of remission, when symptoms improve or even disappear for a time. The first year or two after diagnosis is often the most challenging, as this is when symptoms tend to be most prominent and the disease may progress. However, with appropriate treatment, many patients find that their condition stabilizes over time.^[4][12]

Standard Treatment Options

The first line of treatment for many people with myasthenia gravis involves medications that help improve the communication between nerves and muscles. The most commonly prescribed drug in this category is pyridostigmine bromide, which is sold under brand names such as Mestinon. This medication belongs to a class of drugs called anticholinesterase inhibitors, which work by preventing the breakdown of acetylcholine, a chemical messenger that helps transmit signals from nerves to muscles. By allowing more acetylcholine to remain available at the neuromuscular junction, the medication helps muscles contract more effectively and reduces weakness.^[8][9]

Pyridostigmine is usually taken several times a day because its effect lasts only a few hours. For some people with mild symptoms, particularly those with ocular myasthenia gravis, this medication alone may be sufficient to control their condition. The typical approach is to start with a low dose and gradually adjust it based on how the person responds. However, pyridostigmine does not work for everyone, and it only provides temporary symptom relief rather than addressing the underlying immune system problem.^[9][11]

Common side effects of pyridostigmine include stomach cramps, diarrhea, increased saliva production, and muscle twitching. These effects occur because the medication also affects other areas where acetylcholine is active, not just the muscles. If these side effects become bothersome, doctors may prescribe additional medications to help manage them or adjust the dose.^[9][14]

When pyridostigmine alone is not enough to control symptoms, or when the condition is more severe, doctors typically add medications that suppress the immune system. This is because myasthenia gravis is an autoimmune disease, meaning the body’s immune system mistakenly attacks healthy tissues. In this case, the immune system produces antibodies that block or destroy the receptors on muscle cells that receive signals from nerves.^[5][7]

Corticosteroids, particularly prednisone, are the most commonly used immunosuppressive medications for myasthenia gravis. These drugs reduce the activity of the immune system, which helps stop it from attacking the neuromuscular junction. Prednisone can be very effective at controlling symptoms and is often started when anticholinesterase inhibitors are not providing adequate relief. In some cases, particularly when swallowing or breathing problems are present, prednisone may be started in a hospital setting where the patient can be closely monitored.^[9][11]

The typical approach with prednisone is to start with a higher dose to gain control of symptoms, then gradually reduce to the lowest effective dose. Many patients are advised to take the medication every other day rather than daily, which can help reduce side effects. However, long-term use of corticosteroids can cause significant side effects including weight gain, increased appetite, mood changes, elevated blood sugar, weakened bones, increased risk of infections, and changes in appearance such as facial swelling. Because of these potential problems, doctors try to minimize the dose and duration of steroid treatment whenever possible.^[9][12]

To reduce dependence on steroids or when steroids cause unacceptable side effects, doctors may add other immunosuppressive medications. Azathioprine (Imuran) is one of the most commonly used alternatives. This medication also suppresses the immune system but works through a different mechanism than steroids. One important consideration with azathioprine is that it can take three months or longer before patients begin to feel its benefits, so patience is required. Regular blood tests are necessary to monitor for potential side effects, including effects on the liver and bone marrow.^[9][11]

Other immunosuppressive medications that may be used for myasthenia gravis include mycophenolate mofetil (CellCept), cyclosporine, tacrolimus, and cyclophosphamide. Each of these drugs has its own profile of effectiveness and potential side effects. Mycophenolate mofetil, for example, may take around six months before providing noticeable benefit. These medications are typically reserved for patients who do not respond adequately to first-line treatments or who cannot tolerate steroids.^[11][12]

For patients with severe symptoms or those experiencing a myasthenic crisis, which is a life-threatening complication involving severe weakness of breathing muscles, more immediate interventions are needed. Two rapid-acting treatments are available: plasmapheresis and intravenous immunoglobulin (IVIg). Plasmapheresis, also called plasma exchange, is a procedure that removes harmful antibodies from the blood. During this treatment, blood is removed from the body, filtered to remove antibodies, and then returned. IVIg involves infusing antibodies from healthy donors, which is thought to help modulate the immune system. Both treatments can provide rapid but temporary improvement and are often used to stabilize patients during a crisis or before surgery.^[11][12]

Surgical Treatment: Thymectomy

Surgery to remove the thymus gland, called a thymectomy, is an important treatment option for many people with myasthenia gravis. The thymus is a small gland located in the chest that plays a role in immune system development. Many people with myasthenia gravis have an abnormally large thymus gland, and about 10% have a tumor of the thymus called a thymoma. Even when a thymoma is not present, removing the thymus can lead to significant improvement in myasthenia symptoms over time.^[4][5]

A landmark clinical trial called the MGTX trial provided clear evidence that thymectomy is beneficial for patients with generalized myasthenia gravis who have antibodies against acetylcholine receptors and are up to 65 years of age. The surgery was shown to reduce symptoms, decrease the need for immunosuppressive medications, and reduce the chances of requiring hospitalization for worsening symptoms. However, it’s important to understand that improvement after thymectomy usually occurs gradually. Most patients begin to notice benefits within the first few months after surgery, but improvement may continue for one to two years or even longer.^[9][12]

Modern surgical techniques have made thymectomy safer and recovery easier than in the past. Many centers now use minimally invasive approaches, including robotic-assisted surgery, which involves smaller incisions, less pain, and shorter hospital stays compared to traditional open surgery. Recovery typically requires several weeks of rest, which patients need to factor into their planning, particularly regarding work and daily activities. If a thymoma is present, removing the thymus is usually recommended even if it may not dramatically improve myasthenia symptoms, because thymomas can cause other problems if left to grow.^[9][12]

Promising Treatments in Clinical Trials

Medical research has made remarkable progress in developing new treatments for myasthenia gravis in recent years. Before 2017, there were no medications specifically approved by the U.S. Food and Drug Administration (FDA) for myasthenia gravis, and doctors had to use medications approved for other conditions. Now, several innovative therapies have been approved, and many more are being tested in clinical trials around the world, including in the United States, Europe, and other regions.^[13]

One of the most significant recent advances involves a class of drugs called neonatal Fc receptor blockers. These medications work by interfering with the recycling of antibodies in the body. Normally, antibodies are recycled and reused by the immune system through a mechanism involving the neonatal Fc receptor. By blocking this receptor, these drugs allow harmful antibodies to be broken down and eliminated more quickly from the body. Three drugs in this category have been approved: efgartigimod alfa (Vyvgart), which is given as an intravenous infusion, rozanolixizumab (Rystiggo), and nipocalimab (Imaavy). Clinical trials have shown that these medications can reduce muscle weakness and improve quality of life for people with generalized myasthenia gravis who have antibodies against acetylcholine receptors.^[11][13]

Another innovative approach involves complement inhibitors. The complement system is part of the immune system that helps antibodies damage cells. In myasthenia gravis, complement proteins contribute to the destruction of acetylcholine receptors at the neuromuscular junction. By blocking specific complement proteins, these medications can prevent or reduce this damage. Three complement inhibitors are now available: eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq). These drugs are typically reserved for patients with more severe or refractory disease because they are expensive and require regular infusions or injections. Patients taking complement inhibitors also need vaccination against certain bacteria because blocking complement can increase infection risk.^[11]

Rituximab is another medication that has shown promise in treating myasthenia gravis, particularly in patients whose disease does not respond well to standard treatments. Rituximab is a B-cell directed therapy that works by targeting and eliminating B cells, which are the immune cells that produce antibodies. This medication was originally developed for cancer and other autoimmune diseases but has been found helpful for some myasthenia gravis patients, especially those with antibodies against muscle-specific kinase (MuSK). Rituximab is given as an intravenous infusion, typically in a series of doses.^[11][12]

Clinical trials for myasthenia gravis typically progress through three phases. Phase I trials focus primarily on safety, involving small numbers of participants to determine whether a new treatment causes harmful effects and to identify the appropriate dose range. Phase II trials expand to larger groups of patients and begin to evaluate whether the treatment is effective at improving symptoms or other measures of disease activity. Phase III trials involve even larger numbers of patients and compare the new treatment against standard treatments or placebo to definitively establish effectiveness and safety. Many of the recently approved medications for myasthenia gravis completed successful Phase III trials showing measurable improvements in muscle strength, reduction in symptoms, and acceptable safety profiles.^[13]

Researchers are also exploring entirely new approaches to treating myasthenia gravis. Some studies are investigating whether specific modifications to existing immunosuppressive drugs can make them more effective or reduce side effects. Others are looking at combination therapies that use multiple medications with different mechanisms of action. Scientists are also studying the different types of antibodies that can cause myasthenia gravis, as understanding these differences may lead to more targeted treatments. About 10% of people with myasthenia gravis do not have detectable antibodies against the acetylcholine receptor or muscle-specific kinase, and research is ongoing to identify other antibodies and develop specific treatments for these patients.^[13]

Patients interested in participating in clinical trials should discuss this option with their neurologist. Clinical trial participation offers the opportunity to access promising new treatments before they become widely available and contributes to advancing medical knowledge that will help future patients. Information about ongoing clinical trials for myasthenia gravis can be found through patient organizations, medical centers specializing in neuromuscular disorders, and clinical trial registries. Eligibility for trials varies depending on factors such as disease severity, previous treatments, antibody status, and other health conditions.^[11]

Most common treatment methods

• Acetylcholinesterase Inhibitors
  • Pyridostigmine bromide (Mestinon, Regonol) – helps improve nerve-to-muscle signal transmission by preventing breakdown of acetylcholine
  • Usually taken several times daily as effects last only a few hours
  • May be sufficient for mild symptoms, particularly ocular myasthenia gravis
  • Common side effects include stomach cramps, diarrhea, and muscle twitching
• Corticosteroids
  • Prednisone – most commonly used steroid to reduce immune system activity
  • Often started in hospital for patients with swallowing or breathing problems
  • Typically prescribed every other day at the lowest effective dose
  • Long-term use can cause weight gain, mood changes, increased infection risk, and bone weakening
• Other Immunosuppressants
  • Azathioprine (Imuran) – takes approximately 3 months to show benefits, requires regular blood monitoring
  • Mycophenolate mofetil (CellCept) – may take around 6 months for noticeable benefit
  • Cyclosporine – alternative immunosuppressant with different mechanism of action
  • Tacrolimus, Cyclophosphamide – reserved for difficult-to-treat cases
• Neonatal Fc Receptor Blockers
  • Efgartigimod alfa (Vyvgart) – given as intravenous infusion, blocks antibody recycling
  • Rozanolixizumab (Rystiggo) – newer Fc receptor blocker
  • Nipocalimab (Imaavy) – recently approved Fc receptor blocker
  • Help reduce harmful antibodies by preventing their recycling in the body
• Complement Inhibitors
  • Eculizumab (Soliris) – blocks complement proteins that damage muscle receptors
  • Ravulizumab (Ultomiris) – longer-acting complement inhibitor
  • Zilucoplan (Zilbrysq) – newer complement inhibitor option
  • Require regular infusions or injections and vaccination against certain bacteria
• B-Cell Directed Therapy
  • Rituximab – eliminates B cells that produce harmful antibodies
  • Particularly effective for patients with MuSK antibodies
  • Given as intravenous infusion in a series of doses
  • Used for refractory cases that don’t respond to standard treatments
• Rapid-Acting Treatments
  • Plasmapheresis (plasma exchange) – removes harmful antibodies from blood through filtration
  • Intravenous Immunoglobulin (IVIg) – infusion of antibodies from healthy donors
  • Subcutaneous Immunoglobulin (Hizentra) – alternative delivery method for immunoglobulin
  • Used for myasthenic crisis or to stabilize patients before surgery
  • Provide rapid but temporary improvement in symptoms
• Surgery
  • Thymectomy – surgical removal of the thymus gland
  • Beneficial for patients with acetylcholine receptor antibodies up to age 65
  • Improvement occurs gradually over months to years after surgery
  • Minimally invasive and robotic-assisted techniques now available
  • Reduces need for medications and risk of hospitalization
  • Mandatory when thymoma (thymus tumor) is present